AbbVie (NYSE: ABBV) has announced positive results from a head-to-head Phase IIIb/IV clinical trial comparing its JAK inhibitor Rinvoq (upadacitinib) with Sanofi’s (NASDAQ: SNY) interleukin blocker Dupixent (dupilumab) in patients with moderate-to-severe atopic dermatitis. The trial demonstrated that Rinvoq was superior in improving eczema area and severity as well as pruritus intensity, with 19.9% of participants showing improvement compared to 8.9% with Dupixent.
In addition to the primary endpoint, AbbVie’s oral tablet also showed better results than Sanofi’s injectable drug in secondary endpoints at week 16, with a skin clearance rate of 40.8% for Rinvoq versus 22.5% for Dupixent, and a no itch to little itch rate of 30.2% versus 15.5%. The safety profile of Rinvoq was found to be consistent with previous studies.
AbbVie is actively developing Rinvoq for the treatment of a range of immune-mediated diseases, including alopecia areata, ankylosing spondylitis, atopic dermatitis, axial spondyloarthritis, Crohn’s disease (CD), giant cell arteritis, hidradenitis suppurativa, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus (SLE), Takayasu arteritis, ulcerative colitis (UC), and vitiligo.- Flcube.com
